KR20090118994A - 하부요로증상을 치료하기 위한 알파-2-델타 리간드 - Google Patents

하부요로증상을 치료하기 위한 알파-2-델타 리간드 Download PDF

Info

Publication number
KR20090118994A
KR20090118994A KR1020097020629A KR20097020629A KR20090118994A KR 20090118994 A KR20090118994 A KR 20090118994A KR 1020097020629 A KR1020097020629 A KR 1020097020629A KR 20097020629 A KR20097020629 A KR 20097020629A KR 20090118994 A KR20090118994 A KR 20090118994A
Authority
KR
South Korea
Prior art keywords
methyl
acid
compounds
alpha
luts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097020629A
Other languages
English (en)
Korean (ko)
Inventor
챨스 프라이스 쥬니어 테일러
앤드류 죤 쑈르프
시몬 렘프리어 웨스트브룩
데이비드 위르겐 우스트로우
Original Assignee
워너-램버트 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32599054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090118994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0302657A external-priority patent/GB0302657D0/en
Application filed by 워너-램버트 캄파니 엘엘씨 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20090118994A publication Critical patent/KR20090118994A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
KR1020097020629A 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드 Ceased KR20090118994A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US60/433,491 2002-12-13
GB0302657A GB0302657D0 (en) 2003-02-05 2003-02-05 Method of treatment
GB0302657.2 2003-02-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077018918A Division KR20070091049A (ko) 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드

Publications (1)

Publication Number Publication Date
KR20090118994A true KR20090118994A (ko) 2009-11-18

Family

ID=32599054

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097020629A Ceased KR20090118994A (ko) 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드
KR1020077018918A Ceased KR20070091049A (ko) 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드
KR1020057010639A Ceased KR20050085563A (ko) 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020077018918A Ceased KR20070091049A (ko) 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드
KR1020057010639A Ceased KR20050085563A (ko) 2002-12-13 2003-12-03 하부요로증상을 치료하기 위한 알파-2-델타 리간드

Country Status (21)

Country Link
EP (2) EP1572173B1 (https=)
JP (2) JP2006511606A (https=)
KR (3) KR20090118994A (https=)
AT (1) ATE465725T1 (https=)
AU (2) AU2003303041B2 (https=)
BR (1) BR0316572A (https=)
CA (2) CA2679030A1 (https=)
CY (1) CY1110114T1 (https=)
DE (1) DE60332387D1 (https=)
DK (1) DK1572173T3 (https=)
ES (1) ES2341240T3 (https=)
MX (1) MXPA05006333A (https=)
MY (2) MY141007A (https=)
NO (1) NO20053355L (https=)
NZ (2) NZ539972A (https=)
PL (1) PL377657A1 (https=)
PT (1) PT1572173E (https=)
RU (2) RU2331438C2 (https=)
SI (1) SI1572173T1 (https=)
TW (1) TWI340639B (https=)
WO (1) WO2004054560A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621193A3 (en) * 2002-12-20 2006-08-02 Dynogen Pharmaceuticals Inc. Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
WO2004080444A2 (en) * 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
AU2004271796A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
US20080261995A1 (en) * 2005-12-21 2008-10-23 Pfizer Inc. Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
KR101454167B1 (ko) 2007-09-07 2014-10-27 삼성전자주식회사 데이터 압축 및 복원 장치 및 방법
WO2009136375A1 (en) * 2008-05-08 2009-11-12 Pfizer Inc Treatment of interstitial cystitis
WO2010084798A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 ３環性化合物
CA2911298C (en) 2013-05-06 2019-09-17 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
KR102741262B1 (ko) 2017-05-26 2024-12-11 노바쎄이 에스에이 전압-게이팅된 칼슘 채널 보조 서브유닛 α2δ 및 이의 용도

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
JPS4966691A (https=) 1972-10-30 1974-06-27
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4026894A (en) 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1561411A (en) 1977-02-25 1980-02-20 Science Union & Cie 2-phenoxyphenyl pyrrolidines and pharmaceutical compositions containing them
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2421888A1 (fr) 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4885367A (en) 1987-11-19 1989-12-05 Taisho Pharmaceutical Co., Ltd. Sulfonanilide compounds
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
ZA923283B (en) 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
FR2687155B1 (fr) 1992-02-12 1995-05-19 Roussel Uclaf Nouveaux derives hexapeptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives.
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
JP3856816B2 (ja) 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
ATE135697T1 (de) 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivate
DE69319551T2 (de) 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
EP0764644A1 (en) 1993-01-15 1997-03-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
CA2113787A1 (en) 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
ES2141916T3 (es) 1993-11-30 2000-04-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO1995028397A1 (en) 1994-04-14 1995-10-26 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
WO1995030652A1 (en) 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US6143747A (en) 1995-01-20 2000-11-07 G. D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ES2183935T3 (es) 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
CA2189355A1 (en) 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
CA2575902C (en) 1995-07-21 2010-06-08 Tactical Therapeutics Inc Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
DE59605948D1 (de) 1995-07-21 2000-11-02 Nycomed Austria Gmbh Linz Derivate von benzosulfonamiden als hemmer des enzym cyclooxygenase ii
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5981576A (en) 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
EP0888325B1 (en) 1996-02-07 2002-05-29 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
WO1997033859A1 (en) 1996-03-14 1997-09-18 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
HU224720B1 (en) 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
SK285353B6 (sk) 1996-04-12 2006-11-03 G. D. Searle & Co. Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
JP3978250B2 (ja) * 1996-08-16 2007-09-19 株式会社フジモト・コーポレーション テストステロン５α−リダクターゼ阻害剤
ATE361909T1 (de) 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
DE69810938T2 (de) 1997-04-11 2003-11-06 Grelan Pharmaceutical Co., Ltd. Pyrazolderivate und sie enthaltende cox-inhibitoren
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
EP0977756A1 (en) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0994858A1 (en) 1997-06-30 2000-04-26 Ortho-McNeil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
WO2000024719A1 (en) 1998-10-27 2000-05-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US5925769A (en) 1997-09-09 1999-07-20 Ortho Pharmaceutical, Corp. Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents
US6046217A (en) 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6140515A (en) 1997-09-24 2000-10-31 Merck & Co., Inc. Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
ATE323067T1 (de) 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
US6080876A (en) 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6133292A (en) 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CN1131855C (zh) 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
CA2304967C (en) 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
SI1045839T1 (en) 1997-12-16 2004-06-30 Warner-Lambert Company Llc Novel amines as pharmaceutical agents
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
HRP20000712A2 (en) 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
AU3953899A (en) * 1998-05-27 1999-12-13 Nippon Shinyaku Co. Ltd. Cyclooxygenase-2 inhibitors
EP1085845A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of cyclooxygenase-2
EP0967777A3 (de) 1998-06-26 2000-01-05 Siemens Aktiengesellschaft Verfahren zur Übertragung von Informationen im Teilnehmeranschlussbereich
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
EP1123296B1 (en) 1998-10-23 2003-09-17 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6077869A (en) 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
BR0008958A (pt) 1999-02-23 2001-11-27 Pfizer Prod Inc Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc
EP1977745B1 (en) * 1999-04-08 2010-04-07 Warner-Lambert Company LLC Treatment of incontinence
ES2317839T3 (es) 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
US6376519B1 (en) 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6077868A (en) 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002481A0 (en) 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
US6083969A (en) 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
NZ518309A (en) * 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
WO2001094347A1 (en) 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
EP1313736B1 (en) 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
DE10035718A1 (de) 2000-07-21 2002-02-07 Boehringer Werkzeugmaschinen Werkzeugmaschine
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
EP1305313A1 (en) 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
MXPA03002090A (es) 2000-09-14 2003-06-19 Gruenenthal Gmbh °-tio-aminoacidos.
PE20021046A1 (es) 2000-09-30 2002-12-14 Gruenenthal Chemie Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
WO2002028858A2 (en) 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
EP1335923B1 (en) 2000-10-03 2006-07-12 Lilly Icos LLC Condensed pyridoindole derivatives
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
GB2367869B (en) 2000-10-14 2004-10-06 Trw Ltd Rear-axle demand for use with front push-through in electrohydraulic (EHB) braking systems
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
MXPA03004023A (es) 2000-11-08 2004-02-12 Lilly Icos Llc Compuestos quimicos.
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
EP1337272A2 (en) * 2000-11-30 2003-08-27 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
JP4220779B2 (ja) 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
EP1372656B1 (en) 2001-03-16 2005-06-22 Pfizer Limited Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
GB0106631D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
SK12822003A3 (sk) 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
KR200245823Y1 (ko) 2001-06-08 2001-10-22 김영남 물감튜브가 달린 그림붓
DE10127980C1 (de) 2001-06-08 2003-01-16 Ovd Kinegram Ag Zug Diffraktives Sicherheitselement
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
DE50307963D1 (de) 2002-05-23 2007-09-27 Karsten Koenig Verfahren zum transfer von molekülen in vitale zellen mittels laserstrahlung sowie anordnung zur durchführung des verfahrens
ES2288641T3 (es) 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP3837696A1 (en) 2018-08-16 2021-06-23 Life Technologies Corporation System and method for automated reagent verification

Also Published As

Publication number Publication date
CA2509605A1 (en) 2004-07-01
HK1083010A1 (zh) 2006-06-23
DK1572173T3 (da) 2010-06-14
NO20053355D0 (no) 2005-07-11
AU2008233202A1 (en) 2008-11-13
PT1572173E (pt) 2010-05-10
RU2005118071A (ru) 2006-01-27
BR0316572A (pt) 2005-10-04
AU2008233202B2 (en) 2011-02-24
ATE465725T1 (de) 2010-05-15
KR20050085563A (ko) 2005-08-29
TW200424153A (en) 2004-11-16
CY1110114T1 (el) 2015-01-14
JP2006511606A (ja) 2006-04-06
CA2509605C (en) 2010-10-05
EP2196201A2 (en) 2010-06-16
AU2003303041A1 (en) 2004-07-09
RU2008108841A (ru) 2009-09-20
NZ539972A (en) 2008-05-30
TWI340639B (en) 2011-04-21
WO2004054560A1 (en) 2004-07-01
MXPA05006333A (es) 2005-08-26
RU2331438C2 (ru) 2008-08-20
NZ567457A (en) 2009-08-28
AU2003303041B2 (en) 2008-07-24
EP2196201A3 (en) 2010-12-08
ES2341240T3 (es) 2010-06-17
MY141007A (en) 2010-02-12
PL377657A1 (pl) 2006-02-06
KR20070091049A (ko) 2007-09-06
MY146794A (en) 2012-09-28
JP2011168606A (ja) 2011-09-01
NO20053355L (no) 2005-07-11
SI1572173T1 (sl) 2010-08-31
EP1572173A1 (en) 2005-09-14
EP1572173B1 (en) 2010-04-28
CA2679030A1 (en) 2004-07-01
DE60332387D1 (de) 2010-06-10

Similar Documents

Publication Publication Date Title
CN100430048C (zh) 治疗下泌尿道症状的α-2-δ配体
AU2008233202B2 (en) Alpha-2-delta ligand to treat lower urinary tract symptoms
US7419981B2 (en) Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2013292046C1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
EP1536782B1 (en) Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain
US20110039899A1 (en) Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH
AU2004271800A1 (en) Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US20040092522A1 (en) Synergistic combinations
ES2965293T3 (es) Compuestos y composiciones que comprenden los mismos para el tratamiento de la hipertensión o falla cardíaca
HK1130017A (en) Pharmaceutical product containing an alpha-2-delta ligand and the use thereof
HK1083010B (en) Alpha-2-delta ligand to treat lower urinary tract symptoms
IL168494A (en) Alpha-2-delta ligand to treat lower urinary tract symptoms

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091001

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091030

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100119

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20111018

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I